uniQure N.V. (QURE) · Nov 4, 2026 · Earnings
Miss — Revenue $5.2M vs ~$6.18M consensus; EPS $(0.88) vs ~$(0.92) consensus
uniQure earnings show a revenue miss despite narrower losses and cash runway into 2030 as AMT-130 moves through FDA review.
uniQure is a gene-therapy developer moving its Huntington’s disease program AMT-130 from clinical development toward a potential commercial launch, with the BLA under Priority Review and a confirmatory study being prepared. The company had already signaled this direction and extended its expected cash runway into 2030 in its second-quarter update, so this quarter adds limited strategic surprise.
| Metric | Current | Comparison | Consensus / prior balance |
|---|---|---|---|
| Revenue (Revenues) | $5.2M (-$1.0M) | $3.7M | ~$6.18M |
| Basic and diluted EPS (Net loss) | $(0.88) | $(1.38) | ~$(0.92) |
| Net loss (Net loss) | $61.2M | $80.5M | |
| Cash, equivalents and investments (Cash Position) | $768.4M | $622.5M at Dec. 31, 2025 |
The earnings headline is a revenue miss, not a cash crisis. Third-quarter revenue rose to $5.2 million from $3.7 million, but it fell short of the published consensus near $6.18 million; the increase was driven by license revenue rather than a new commercial product ramp. The loss per share was modestly better than expectations at $0.88 versus roughly $0.92, but that beat does not offset the top-line shortfall.
Spending is moving in the direction required for launch preparation, but the cost base is rising. R&D increased only slightly as process-validation spending fell, while SG&A rose 23% as uniQure recruited staff and added infrastructure for a potential ifezuntirgene inilparvovec launch. This is strategically consistent with the AMT-130 plan, but it increases the importance of regulatory execution because revenue has not yet begun to absorb those commercial costs.
Liquidity is the strongest part of the update, but it was largely expected. Cash, cash equivalents and investments reached $768.4 million, up from $622.5 million at year-end, and management reiterated funding into 2030. 〔0〕 That removes near-term financing pressure from the story, but it does not resolve the central question: whether AMT-130 can clear FDA review and support the planned confirmatory path.
Bottom line: This was a modest earnings miss with a narrow EPS beat and better liquidity, while the business remains primarily a regulatory bet on AMT-130. The quarter slightly weakens the operating read, but it does not materially change the company’s core story. 〔1〕
FDA review of the AMT-130 BLA
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!